EW|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.74 | - | - |
| Q2'26 | $0.74 | $0.78 | +5.1% |
| Q1'26 | $0.75 | $0.78 | +4.1% |
| Q4'25 | $0.69 | $0.58 | -16.0% |
| Q3'25 | $0.59 | $0.67 | +12.6% |
| Q2'25 | $0.62 | $0.67 | +7.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.7B | - | - |
| Q2'26 | $1.7B | $1.7B | +2.4% |
| Q1'26 | $1.6B | $1.6B | +0.3% |
| Q4'25 | $1.6B | $1.6B | +0.2% |
| Q3'25 | - | $1.6B | - |
| Q2'25 | - | $1.5B | - |
Market Data
EW Stock Snapshot
EW is currently trading at $89.72, giving Edwards Lifesciences Corporation a market cap of 51.62B and a P/E ratio of 51.4. Today's range spans $88.77–$90.36, with shares opening at $89.44 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY).
Over the past year EW has traded between $72.30 and $96.29 - the current price is +24.1% off the 52-week low and -6.8% from the high. 42 analysts cover the stock with a Buy consensus and a mean 12-month target of $100.96 (range $84.00–$110.00), implying upside of +12.5%.
In the Healthcare peer group, Edwards Lifesciences Corporation (EW) stands out for a BUY signal backed by aligned sentiment - score 91/100, sentiment neutral at -/100, price $89.72 (in the upper portion of its 52-week range). (P/E: 51.4) With 51.62B in market cap, this is large enough to feature on institutional watch lists but small enough to re-rate meaningfully on a positive earnings surprise. The 52-week span of $72.30–$96.29 shows the stock has already proven it can make significant moves.
The combination of a BUY signal (91/100) and neutral news sentiment (-/100) puts EW on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 51.62B in Healthcare market cap without immediately moving the stock. At $89.72 (in the upper portion of its 52-week range in the $72.30–$96.29 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Edwards Lifesciences Corporation (EW)
Edwards Lifesciences Corporation (EW) is a prominent player in the medical technology sector, focusing on advanced solutions for cardiovascular diseases. The company's strategic emphasis lies in the development and commercialization of transcatheter heart valve technologies, particularly for aortic valve replacement (TAVR). This specialization positions Edwards at the forefront of minimally invasive cardiac procedures, addressing a significant and growing patient population.
The company's product portfolio extends beyond TAVR to include critical mitral and tricuspid valve repair and replacement systems, alongside surgical structural heart solutions. This comprehensive offering allows Edwards to cater to a wide array of patient needs and clinical scenarios within the structural heart market. The integration of advanced technologies like the Edwards SAPIEN and PASCAL PRECISION systems underscores the company's commitment to innovation and patient outcomes.
Edwards Lifesciences has demonstrated consistent revenue growth, with recent performance indicating an upward trend in sales. While earnings per share (EPS) have experienced some volatility, often linked to strategic investments in its TAVR segment, the company has a history of meeting or exceeding revenue expectations. This revenue trajectory, coupled with ongoing product development, forms a key aspect of the investment thesis.
TAVR Leadership
Edwards Lifesciences is a leader in the rapidly expanding transcatheter aortic valve replacement (TAVR) market.
Significant investments in TAVR technology are driving sales growth and market share gains.
The company's SAPIEN family of valves represents a cornerstone of its minimally invasive cardiac solutions.
Structural Heart Portfolio
The company offers a broad range of solutions for mitral and tricuspid valve repair and replacement.
Brands like PASCAL PRECISION and Cardioband highlight innovation in complex valve interventions.
This diversified portfolio supports a comprehensive approach to structural heart disease management.
Revenue Growth
Edwards Lifesciences has consistently delivered revenue growth, reflecting strong market demand.
Recent performance shows an upward trend in sales, supported by its core TAVR business.
The company generally meets or surpasses analyst revenue estimates, indicating operational strength.
Valuation Metrics
The stock currently trades at a Price-to-Earnings (P/E) ratio of approximately 45.59.
Its 52-week trading range is between $65.94 and $87.89, indicating recent price fluctuations.
The market capitalization stands at over $48.9 billion, reflecting its significant presence in the medical device industry.
Investment & Spending
Increased spending on TAVR technology development and commercialization impacts short-term profitability.
These strategic investments are crucial for maintaining leadership and capturing future market growth.
Investors should monitor the balance between R&D expenditure and EPS performance.
Positioning EW
Edwards Lifesciences represents a strategic investment in the growing structural heart market, particularly TAVR. Exposure may be warranted for investors seeking exposure to medical device innovation and consistent revenue expansion. Consider increasing positions on pullbacks that do not reflect fundamental shifts in TAVR market growth or competitive positioning.
Analyst Price Targets for EW
Wall Street's current consensus view on Edwards Lifesciences Corporation (EW), based on the most recently tracked analyst coverage.
Reflects the most recently tracked analyst ratings for EW and may lag real-time updates. Not a recommendation to buy or sell.
Risk Factors
Edwards Lifesciences faces risks primarily tied to the success of its innovative cardiovascular technologies and the regulatory environment. Investor sentiment can shift based on clinical trial outcomes, product adoption rates, and competitive pressures in the high-stakes medical device market.
- TAVR Competition
Intensifying competition in the transcatheter aortic valve replacement (TAVR) market poses a significant threat. New entrants or improved competitor products could erode Edwards' market share and pricing power. This risk would materialize if competitors launch superior technologies or aggressively price their offerings, impacting sales and profitability.
- Clinical Trial Risk
The company's growth relies heavily on the success of ongoing and future clinical trials for new valve technologies. Unfavorable trial results or delays in regulatory approval could halt product development and commercialization. This would directly impact future revenue streams and investor confidence.
- Reimbursement Changes
Changes in healthcare reimbursement policies for cardiovascular procedures could negatively affect Edwards' revenue. If payers reduce coverage or reimbursement rates for TAVR or other advanced therapies, patient access and company sales could decline. This risk is particularly relevant if government or private insurers alter their coverage decisions.
- Product Recall Risk
As a medical device manufacturer, Edwards Lifesciences is susceptible to product recalls due to manufacturing defects or performance issues. A significant recall could lead to substantial financial costs, reputational damage, and a loss of market trust. This risk would materialize if quality control failures lead to widespread product malfunctions.
EW Competitive Positioning
Edwards Lifesciences Corporation (EW) is tracked alongside these names in Medical Devices on DailyIQ.
EW Recent Earnings History
- Q4 2025
EPS: $0.58 actual vs $0.69 estimate (miss) · Revenue: $1,570M actual vs $1,566M estimate
- Q3 2025
EPS: $0.67 actual vs $0.59 estimate (beat) · Revenue: $1,553M actual
- Q2 2025
EPS: $0.67 actual vs $0.62 estimate (beat) · Revenue: $1,532M actual
- Q1 2025
EPS: $0.64 actual vs $0.6 estimate (beat) · Revenue: $1,413M actual
- Q4 2024
EPS: $0.59 actual vs $0.55 estimate (beat) · Revenue: $1,386M actual
What Moves EW Stock?
Edwards Lifesciences' stock performance is primarily driven by the adoption and expansion of its transcatheter aortic valve replacement (TAVR) technologies. Investor sentiment also reacts to the company's ability to manage R&D investments and achieve consistent revenue growth in a competitive medical device landscape.
TAVR Adoption
The global market for transcatheter aortic valve replacement (TAVR) continues to expand as minimally invasive procedures gain favor over traditional open-heart surgery. Edwards Lifesciences, with its SAPIEN valve platform, is a key player in this growing segment, benefiting from technological advancements and increasing physician and patient acceptance.
Strong TAVR sales growth directly translates to higher revenue and can lead to margin expansion if cost efficiencies are realized. Conversely, any slowdown in adoption, competitive pressures, or reimbursement challenges could negatively impact the stock by signaling slower growth prospects.
R&D Investment
Edwards Lifesciences consistently invests in research and development to innovate its TAVR and other structural heart solutions, including mitral and tricuspid valve technologies. These investments are crucial for maintaining a competitive edge and addressing unmet patient needs.
While R&D spending fuels future growth, significant outlays can temporarily pressure earnings per share, potentially causing short-term stock price dips. Investors weigh these investments against the long-term potential for market leadership and new product revenue streams.
Structural Heart Growth
Beyond TAVR, Edwards Lifesciences offers a comprehensive portfolio for surgical structural heart solutions and repair/replacement of mitral and tricuspid valves. The company's ability to innovate and gain market share across these diverse structural heart indications is a key growth driver.
Success in expanding its footprint in these adjacent structural heart markets can diversify revenue streams and enhance overall company valuation. Any setbacks or competitive gains by rivals in these areas could temper investor enthusiasm and weigh on the stock.
Key insight: Edwards Lifesciences' stock hinges on the sustained growth of its TAVR franchise and its ability to innovate across the broader structural heart market. Investors will closely monitor the balance between aggressive R&D spending and its impact on near-term profitability versus long-term market dominance.
Key Metrics for EW
Edwards Lifesciences' performance hinges on the adoption of its innovative cardiovascular technologies and its ability to manage R&D investments. Investors should monitor key growth and profitability drivers specific to the medical device sector.
Transcatheter Sales: Measures revenue from minimally invasive heart valve replacement procedures. Strong growth indicates successful TAVR adoption and market penetration for Edwards Lifesciences; slowing growth could signal competitive pressure or market saturation. This is crucial as TAVR is a primary growth engine for EW's stock valuation.
Surgical Heart Sales: Tracks revenue from traditional open-heart surgical valve solutions. Stable or growing sales here demonstrate Edwards Lifesciences' continued strength in its legacy business; declines may suggest a shift away from surgical options. This metric is important for understanding the overall health of EW's structural heart franchise.
Gross Margin: Reflects the profitability of Edwards Lifesciences' products after accounting for cost of goods sold. Expanding margins suggest efficient manufacturing and pricing power; contracting margins could indicate rising production costs or pricing pressures. This is a key indicator of EW's operational efficiency and pricing power.
R&D Investment: Monitors the company's spending on developing new cardiovascular technologies. Increased R&D spending signals a commitment to innovation and future growth for Edwards Lifesciences; a decrease might suggest a slowdown in pipeline development. This metric is vital for assessing EW's long-term competitive positioning and growth potential.
Operating Income: Represents Edwards Lifesciences' profitability from its core business operations before interest and taxes. Growth in operating income indicates effective cost management and sales growth; a decline suggests challenges in either area. This is a fundamental measure of EW's overall business performance and profitability.
Frequently Asked Questions About EW
Is Edwards Lifesciences (EW) stock a good investment?
Edwards Lifesciences (EW) stock may be considered by investors seeking exposure to the medical device sector, particularly in cardiovascular solutions. The company's focus on transcatheter heart valve replacement (TAVR) technology is a key growth driver. Investors should evaluate its competitive positioning, innovation pipeline, and long-term market trends in structural heart disease.
What drives Edwards Lifesciences (EW) stock price?
The stock price of Edwards Lifesciences (EW) is primarily influenced by sales growth in its TAVR and other structural heart device segments. Advancements in its product pipeline, regulatory approvals, and market adoption rates for minimally invasive procedures are significant factors. Investor sentiment regarding the company's ability to manage expenses related to its growth initiatives also plays a role.
Does Edwards Lifesciences (EW) pay a dividend?
Edwards Lifesciences (EW) currently does not pay a regular dividend to its shareholders. The company has historically chosen to reinvest its earnings back into the business to fund research and development, expand its product portfolio, and support its growth strategies. Investors interested in income generation may need to consider other investment options.
What are the risks of investing in Edwards Lifesciences (EW) stock?
Risks associated with Edwards Lifesciences (EW) include intense competition within the medical device industry, potential regulatory hurdles for new products, and challenges in achieving consistent earnings growth due to significant R&D and sales investments. Reimbursement policies from healthcare payers and the success of its TAVR technology adoption are also critical considerations.
How is Edwards Lifesciences (EW) performing in its earnings reports?
Edwards Lifesciences (EW) has shown revenue growth in recent quarters, driven by its TAVR segment. However, earnings per share (EPS) have experienced some volatility, partly due to increased spending on growth initiatives. The company has a mixed record of beating analyst EPS estimates, underscoring the importance of closely monitoring its financial disclosures.
What is the investment thesis for Edwards Lifesciences (EW)?
The bull case for Edwards Lifesciences (EW) centers on its leadership position in the rapidly expanding transcatheter aortic valve replacement (TAVR) market. Continued innovation, a strong pipeline for mitral and tricuspid valve solutions, and an aging global population requiring cardiovascular interventions support its long-term growth potential. The company's ability to execute on its strategic investments is key to realizing this thesis.
How does Edwards Lifesciences (EW) manage its capital?
Edwards Lifesciences (EW) primarily allocates capital towards research and development to fuel its innovation pipeline, particularly in TAVR and other structural heart technologies. The company also invests in expanding manufacturing capacity and its global commercial infrastructure. Share repurchases have been utilized, but dividend payments are not currently part of its capital return strategy.
What is the valuation of Edwards Lifesciences (EW) stock?
The valuation of Edwards Lifesciences (EW) stock can be assessed by looking at its price-to-earnings (P/E) ratio relative to its historical average and industry peers. Its market capitalization indicates a significant player in the medical device space. Investors often consider future growth prospects and profitability when determining if the current stock price reflects fair value.
What are Edwards Lifesciences' (EW) key growth areas?
Edwards Lifesciences' (EW) primary growth engine is its transcatheter aortic valve replacement (TAVR) portfolio, which continues to see strong adoption. The company is also investing in expanding its offerings for mitral and tricuspid valve repair and replacement, addressing significant unmet needs in these areas. Further innovation in surgical structural heart solutions also contributes to its growth.
How does Edwards Lifesciences (EW) compete in the medical device market?
Edwards Lifesciences (EW) competes through its strong focus on innovation and its established leadership in the TAVR market. The company differentiates itself with its comprehensive portfolio of structural heart solutions, including both transcatheter and surgical options. Its direct sales force and deep relationships with cardiologists and cardiac surgeons provide a competitive advantage.
Learn More
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.